<DOC>
	<DOC>NCT01370369</DOC>
	<brief_summary>This is an open-label study of a single and repeated application of three dose levels of topical testosterone in hypogonadal males with morning serum testosterone concentrations &lt; 297 ng/dL.</brief_summary>
	<brief_title>Efficacy, Pharmacokinetics and Safety of Testosterone</brief_title>
	<detailed_description />
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Ages 1865 History of hypogonadism In good health based on medical history, physical examination and clinical laboratory tests Screening morning serum testosterone ≤ 297 ng/dL One or more symptoms of testosterone deficiency (i.e. fatigue, reduced libido or reduced sexual functioning of nonvasculogenic or neurogenic nature) Body mass index (BMI) between 18 and 31 Prostate cancer Palpable prostatic mass(es) Generalized skin irritation or significant skin disease Use of any medications that could be considered anabolic (e.g. dehydroepiandrosterone (DHEA)) or could interfere with androgen metabolism (e.g. spironolactone, finasteride, ketoconazole) Clinically significant anemia or renal dysfunction Hyperparathyroidism or uncontrolled diabetes Serum PSA Levels; ≥ 4ng/mL History of cardiovascular disease Use of estrogens, Gonadotropinreleasing hormone (GnRH) agonists/antagonist, human growth hormone (hGH), (within previous 12 months) Use of testosterone products (within eight months for parenteral products, or six weeks for other preparations)</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>